Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Non Operating Income (2019 - 2025)

Historic Non Operating Income for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $14.4 million.

  • Avidity Biosciences' Non Operating Income fell 1901.22% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.7 million, marking a year-over-year increase of 4177.96%. This contributed to the annual value of $56.6 million for FY2024, which is 14225.34% up from last year.
  • Per Avidity Biosciences' latest filing, its Non Operating Income stood at $14.4 million for Q3 2025, which was down 1901.22% from $13.8 million recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' Non Operating Income registered a high of $18.7 million during Q4 2024, and its lowest value of -$95000.0 during Q4 2021.
  • Moreover, its 5-year median value for Non Operating Income was $5.6 million (2023), whereas its average is $6.8 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first plummeted by 62777.78% in 2021, then skyrocketed by 1219090.91% in 2022.
  • Over the past 5 years, Avidity Biosciences' Non Operating Income (Quarter) stood at -$95000.0 in 2021, then soared by 2998.95% to $2.8 million in 2022, then skyrocketed by 128.76% to $6.3 million in 2023, then skyrocketed by 197.35% to $18.7 million in 2024, then decreased by 23.32% to $14.4 million in 2025.
  • Its last three reported values are $14.4 million in Q3 2025, $13.8 million for Q2 2025, and $15.7 million during Q1 2025.